SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Cancer medicines on the WHO Model List of Essential Medicines: processes, challenges, and a way forward
8 references·0 citing·31 second hop
Cancer medicines on the WHO Model List of Essential Medicines: processes, challenges, and a way forward (2022)Cancer medicines on the WHO Model List of…The ecosystem of health decision making: from fragmentation to synergy (2022)The ecosystem of health decis…Regulatory and clinical consequences of negative confirmatory trials of accelerated approval cancer drugs: retrospective observational study (2021)Regulatory and clinical conse…Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey (2021)Access to cancer medicines de…A 25-Year Experience of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and Biologics (2018)A 25-Year Experience of US Fo…ESMO International Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in countries outside of Europe (2017)ESMO International Consortium…Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks (2017)Delivery of meaningful cancer…Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received (2016)Updating the American Society…Proposing Essential Medicines to Treat Cancer: Methodologies, Processes, and Outcomes (2015)Proposing Essential Medicines…25 years of the WHO essential medicines lists: progress and challenges (2003)Blood Transfusion Safety in Africa: A Literature Review of Infectious Disease and Organizational Challenges (2011)Promotion of access to essential medicines for non-communicable diseases: practical implications of the UN political declaration (2013)Access to Cancer Therapeutics in Low- and Middle-Income Countries (2016)Bringing down the cost of cancer treatment (2018)A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) (2015)American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options (2015)A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors (2018)Financial toxicity in cancer care: Prevalence, causes, consequences, and reduction strategies (2019)Medical Care Costs Associated with Cancer Survivorship in the United States (2020)Pricing in the Market for Anticancer Drugs (2015)Examining Trends in Cost and Clinical Benefit of Novel Anticancer Drugs Over Time (2018)Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit Score (2019)Association between FDA and EMA expedited approval programs and therapeutic value of new medicines: retrospective cohort study (2020)Health systems financing and the path to universal coverage (2010)Washington State Cancer Patients Found To Be At Greater Risk For Bankruptcy Than People Without A Cancer Diagnosis (2013)Health Care Systems in Low- and Middle-Income Countries (2014)Comparison of Sales Income and Research and Development Costs for FDA-Approved Cancer Drugs Sold by Originator Drug Companies (2019)Please mind the gap—about equity and access to care in oncology (2021)The financial burden of out of pocket payments on medicines among households in Ethiopia: analysis of trends and contributing factors (2023)Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval (2019)Optimal payment systems for health services (1990)Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 (2014)Essential medicines for universal health coverage (2016)Barriers in access to oncology drugs — a global crisis (2022)The Framing of Decisions and the Psychology of Choice (1981)Chapter 12: Interpreting results and drawing conclusions (2011)Cost–effectiveness thresholds: pros and cons (2016)ROBVALU: a tool for assessing risk of bias in studies about people’s values, utilities, or importance of health outcomes (2024)Trends in the approval of cancer therapies by the FDA in the twenty-first century (2023)Clinical Benefit and Regulatory Outcomes of Cancer Drugs Receiving Accelerated Approval (2024)
this work references cited by second hop

References

  • 2016Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received655 cited
  • 2018A 25-Year Experience of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and Biologics298 cited
  • 2021Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey180 cited
  • 2017Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks149 cited
  • 2017ESMO International Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in countries outside of Europe124 cited
  • 2021Regulatory and clinical consequences of negative confirmatory trials of accelerated approval cancer drugs: retrospective observational study112 cited
  • 2022The ecosystem of health decision making: from fragmentation to synergy109 cited
  • 2015Proposing Essential Medicines to Treat Cancer: Methodologies, Processes, and Outcomes99 cited

Cited by

No citing works inside the corpus for this window.

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work